Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Saved in:
| Title: | Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. |
|---|---|
| Authors: | Weber JS; Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA. jeffrey.weber@nyulangone.org., Poretta T; Bristol Myers Squibb, Princeton, NJ, USA., Stwalley BD; Bristol Myers Squibb, Princeton, NJ, USA., Sakkal LA; Bristol Myers Squibb, Princeton, NJ, USA., Du EX; Analysis Group, Inc., Los Angeles, CA, USA., Wang T; Analysis Group, Inc., Los Angeles, CA, USA., Chen Y; Analysis Group, Inc., Los Angeles, CA, USA., Wang Y; Analysis Group, Inc., Los Angeles, CA, USA., Betts KA; Analysis Group, Inc., Los Angeles, CA, USA., Shoushtari AN; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2023 Apr; Vol. 72 (4), pp. 955. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36538061 AccessLevel: 2 PubTypeId: unknown PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Weber+JS%22">Weber JS</searchLink>; Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA. jeffrey.weber@nyulangone.org.<br /><searchLink fieldCode="AU" term="%22Poretta+T%22">Poretta T</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Stwalley+BD%22">Stwalley BD</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Sakkal+LA%22">Sakkal LA</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Du+EX%22">Du EX</searchLink>; Analysis Group, Inc., Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+T%22">Wang T</searchLink>; Analysis Group, Inc., Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Chen+Y%22">Chen Y</searchLink>; Analysis Group, Inc., Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Analysis Group, Inc., Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Betts+KA%22">Betts KA</searchLink>; Analysis Group, Inc., Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Shoushtari+AN%22">Shoushtari AN</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228605732%22">Cancer immunology, immunotherapy : CII</searchLink> [Cancer Immunol Immunother] 2023 Apr; Vol. 72 (4), pp. 955. – Name: TypePub Label: Publication Type Group: TypPub Data: Published Erratum – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>8605732 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0851 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203407004%22">03407004 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Immunol Immunother <i>Subsets: </i>MEDLINE; PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36538061 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s00262-022-03351-w Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 955 Titles: – TitleFull: Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Weber JS – PersonEntity: Name: NameFull: Poretta T – PersonEntity: Name: NameFull: Stwalley BD – PersonEntity: Name: NameFull: Sakkal LA – PersonEntity: Name: NameFull: Du EX – PersonEntity: Name: NameFull: Wang T – PersonEntity: Name: NameFull: Chen Y – PersonEntity: Name: NameFull: Wang Y – PersonEntity: Name: NameFull: Betts KA – PersonEntity: Name: NameFull: Shoushtari AN IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2023 Apr Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1432-0851 Numbering: – Type: volume Value: 72 – Type: issue Value: 4 Titles: – TitleFull: Cancer immunology, immunotherapy : CII Type: main |
| ResultId | 1 |
